**Table S2. Top 20 enriched KEGG pathways in genes up-regulated in neratinib-treated TBCP-1 cells.**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Pathway\_ID** | **Pathway** | **N** | **DE** | **P.DE** |
| path:mmu05215  | Prostate cancer  | 91  | 16  | 0.001256372  |
| path:mmu04010  | MAPK signaling pathway  | 260  | 31  | 0.007958893  |
| path:mmu04216  | Ferroptosis  | 39  | 8  | 0.008090283  |
| path:mmu05225  | Hepatocellular carcinoma  | 158  | 21  | 0.008382806  |
| path:mmu04922  | Glucagon signaling pathway  | 83  | 13  | 0.009547944  |
| path:mmu05220  | Chronic myeloid leukemia  | 76  | 12  | 0.011769239  |
| path:mmu04068  | FoxO signaling pathway  | 117  | 16  | 0.015529344  |
| path:mmu04151  | PI3K-Akt signaling pathway  | 295  | 33  | 0.015726368  |
| path:mmu05161  | Hepatitis B  | 130  | 17  | 0.019422346  |
| path:mmu04115  | p53 signaling pathway  | 63  | 10  | 0.019879695  |
| path:mmu04710  | Circadian rhythm  | 29  | 6  | 0.020094885  |
| path:mmu05206  | MicroRNAs in cancer  | 162  | 20  | 0.021242406  |
| path:mmu05212  | Pancreatic cancer  | 74  | 11  | 0.023628357  |
| path:mmu04931  | Insulin resistance  | 94  | 13  | 0.025385187  |
| path:mmu01524  | Platinum drug resistance  | 75  | 11  | 0.025864225  |
| path:mmu05213  | Endometrial cancer  | 57  | 9  | 0.027317431  |
| path:mmu01521  | EGFR tyrosine kinase inhibitor resistance  | 76  | 11  | 0.02824953  |
| path:mmu05231  | Choline metabolism in cancer  | 96  | 13  | 0.029635403  |
| path:mmu05222  | Small cell lung cancer  | 87  | 12  | 0.031584962  |
| path:mmu04142  | Lysosome  | 117  | 15  | 0.031741052  |